&w=3840&q=100)
Tesla's entry into India to bring innovation in EV insurance space
Mumbai
Listen to This Article
US-based Tesla's entry into India is expected to bring more innovation to the electric vehicle (EV) insurance market in the country, said industry insiders. Tesla's advanced technology features and superior battery quality for vehicles will raise the technology standard, leading insurers to rethink their product offerings in this space.
Tesla launched its Model Y, an electric car with a starting price of ₹60 lakh, earlier this week by opening its first showroom in Mumbai's Bandra Kurla Complex (BKC).
Following the launch, ACKO, Zurich Kotak, and Liberty General announced that they have been selected as the 'preferred insurance partners' for Tesla
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
AU Bank profit rises 16% to 581 cr in Apr-June qtr
Jaipur: AU Small Finance Bank posted a 16% growth in net profit to Rs 581 crore during the first quarter of this financial year. The Jaipur-based bank had earned a net profit of Rs 503 crore in the same quarter of the previous fiscal year. Tired of too many ads? go ad free now The total income rose to Rs 5,189 crore during the June 2025 quarter from Rs 4,278 crore in the same period of FY25, AU Small Finance Bank said in a regulatory filing. Interest earned by the bank improved to Rs 4,378 crore compared to Rs 3,769 crore in the June quarter of FY25. Net interest income rose to Rs 2,045 crore during the quarter against Rs 1,921 crore a year ago. The bank's operating profit also increased to Rs 1,312 crore from Rs 952 crore in the year-ago period. Gross loan portfolio (GLP) grew 18% to Rs 1,17,624 crore compared to Rs 99,792 crore as of Q1 FY25, it said. Similarly, net NPAs, or bad loans, increased to 0.88% against 0.63% in the year-ago period. As a result, provisions and contingencies almost doubled to Rs 533 crore during the first quarter compared to Rs 283 crore a year ago. Provision Coverage Ratio (PCR) stood at 83% at the end of June 2025. However, the capital adequacy ratio of the bank declined to 19.42 per cent from 20.11 per cent in the same quarter of FY25. Commenting on quarterly numbers, AU Small Finance Bank MD and CEO Sanjay Agarwal said, "We have reported another set of consistent performance in a seasonally soft quarter, showing sustainable growth in deposits, assets, and profitability". As the economic cycle strengthens, AU is well-positioned to navigate near-term uncertainties while staying committed to the long-term vision of building a forever bank that can truly scale with sustainability,headded.
Time of India
2 hours ago
- Time of India
Elon Musk says: Back to working 7 days a week and sleeping in the office if ...
Tesla and SpaceX CEO has reiterated that he will go back to his habit of working seven days a week and sleeping in office. Just that this time he has set a condition to this. The condition is his little kids going away somewhere. In a post on Twitter, Musk wrote: 'Back to working 7 days a week and sleeping in the office if my little kids are away'. Elon Musk wrote the post while sharing an old video of his where he can be seen saying: "7 days a week sleeping in the factory, No one should put these many hours into work, this is not good, this is very painful, it hurts my brain and my heart." Elon Musk on working 120 hours in a week Elon Musk spoke about working 120 hours in a week in an interview with Leslie Stahl on Sunday's '60 Minutes' on CBS. In the interview that went live in December 2018, Musk said that he worked on the floor fixing problems and slowdowns in the assembly line as Tesla struggled to ramp up production of Model 3 car. According to Musk, the delays in production pushed the Tesla to the brink. 'It was life or death. We were losing $50 [million], sometimes $100 million a week. Running out of money." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Dubai villas | search ads Get Deals Undo In April of the same year, Musk told 'CBS This Morning' host Gayle King hat he sometimes sleeps at the Tesla factory to show his team that he doesn't ask them to do anything he won't do himself. 'Yeah, I'm sleeping on the factory floor, not because I think that's a fun place to sleep. You know. Terrible,' Musk told King. 'I don't believe like people should be experiencing hardship while the CEO is, like, off on vacation.' Elon Musk said he lived in factory floor for three full years In a November 2022 interview with Baron Capital CEO Ron Baron, Elon Musk said he was 'living in the factory in Fremont, and the one in Nevada, for three years straight. That was my primary residence. 'I slept on the couch at one point, in a tent on the roof, and for a while there, I was just sleeping under my desk, which is out in the open in the factory,' he said. 'It was damn uncomfortable sleeping on that floor and always, when I woke up, I'd smell like metal dust.' Elon Musk said his DOGE team works 120 hours a week In February this year, Elon Musk said he and his team at the Department of Government Efficiency (DOGE) are working 120 hours a week. 'Our bureaucratic opponents optimistically work 40 hours a week,' he added. 'That is why they are losing so fast.' AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
2 hours ago
- Time of India
Zydus Life's plans for cancer biosimilar hit a legal hurdle
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.
